Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$332.29 ▲ +7.74
(+2.38%)
MKT CAP: $9.61B • VOL: 330.5K
52W L $184 52W H $383
KRYS // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $389.1M | $290.5M | $50.7M |
| YoY Revenue Growth % | +33.9% | +473.0% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $161.3M | $65.7M | -$109.6M |
| Operating Margin % | 41.5% | 22.6% | -216.2% |
| Net Income (GAAP) | $204.8M | $89.2M | $10.9M |
| EBITDA (Normalized) | $170.9M | $69.1M | -$107.8M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $200.9M | $123.4M | -$88.8M |
| Capital Expenditures (CapEx) | $12.0M | $4.2M | $2.3M |
| Free Cash Flow (FCF) | $188.9M | $119.2M | -$91.1M |
| FCF Margin % | 48.5% | 41.0% | -179.7% |
| Return on Invested Capital (ROIC %) | 16.4% | 8.0% | -2.7% |
| Cash & Short-Term Equivalents | $496.3M | $344.9M | — |
| Total Debt (Short + Long Term) | $51.4M | $49.3M | $1.24B |
| Total Stockholders' Equity | $1.22B | $946.4M | $2.54B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR KRYS.